{"DataElement":{"publicId":"5581571","version":"1","preferredName":"Lung Tissue Doxorubicin Concentration Solid Phase Microextraction Value","preferredDefinition":"Numeric representation of the measurement of the amount of doxorubicin present in the lung, measured by SMPE (Solid Phase Micro Extraction).","longName":"LNG_DOX_SPME_VAL","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"5581529","version":"1","preferredName":"Lung Tissue Doxorubicin Solid Phase Microextraction Concentration","preferredDefinition":"Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels._An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects._A sampling technique that uses a polymer-coated fiber to absorb to directly extract and concentrate an analyte from a fluid._The quantity of a substance per unit volume or weight; a measure of the amount of substance present in a unit amount of mixture, particularly, the amount of solute dissolved in a solvent. The amounts can be expressed as moles, masses, volumes, or parts.","longName":"5581526v1.0:5581527v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"5581526","version":"1","preferredName":"Lung Tissue","preferredDefinition":"Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.","longName":"C33024","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Tissue","conceptCode":"C33024","definition":"Tissue consisting of an external serous coat, subserous areolar tissue and lung parenchyma. The parenchyma is made up of lobules wound together by connective tissue. A primary lobule consists of a terminal bronchiole, respiratory bronchioles, and alveolar ducts, which communicate with many alveoli, each alveolus being surrounded by a network of capillary blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42648C33-7352-3242-E053-F662850A843E","latestVersionIndicator":"Yes","beginDate":"2016-11-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-11-28","modifiedBy":"ONEDATA","dateModified":"2016-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5581527","version":"1","preferredName":"Doxorubicin Solid Phase Microextraction Concentration","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.:A sampling technique that uses a polymer-coated fiber to absorb to directly extract and concentrate an analyte from a fluid.:The quantity of a substance per unit volume or weight; a measure of the amount of substance present in a unit amount of mixture, particularly, the amount of solute dissolved in a solvent. The amounts can be expressed as moles, masses, volumes, or parts.","longName":"C456:C129962:C41185","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Solid Phase Microextraction","conceptCode":"C129962","definition":"A sampling technique that uses a polymer-coated fiber to absorb to directly extract and concentrate an analyte from a fluid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Concentration","conceptCode":"C41185","definition":"The quantity of a substance per unit volume or weight; a measure of the amount of substance present in a unit amount of mixture, particularly, the amount of solute dissolved in a solvent. The amounts can be expressed as moles, masses, volumes, or parts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42648C33-7364-3242-E053-F662850A843E","latestVersionIndicator":"Yes","beginDate":"2016-11-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-11-28","modifiedBy":"ONEDATA","dateModified":"2016-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42648C33-7375-3242-E053-F662850A843E","latestVersionIndicator":"Yes","beginDate":"2016-11-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-11-28","modifiedBy":"COOPERM","dateModified":"2016-12-07","changeDescription":"Created for Princess Margaret study in Rave as requested by D.Laurence. mc 11/28/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5581453","version":"1","preferredName":"Number 11 digits 4 Decimal Value","preferredDefinition":"Value expressed as a number of 11 digits total, with 4 after the decimal.","longName":"NUM_11_4_VAL","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"11","minValue":null,"maxValue":null,"decimalPlace":"4","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2414933","version":"1","preferredName":"Value","preferredDefinition":"A numerical quantity measured or assigned or computed.","longName":"C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"02772734-9BE5-6ADF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-06","modifiedBy":"ONEDATA","dateModified":"2005-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4262C577-8D23-2305-E053-F662850A1F0B","latestVersionIndicator":"Yes","beginDate":"2016-11-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-11-28","modifiedBy":"COOPERM","dateModified":"2016-12-07","changeDescription":"Created for Princess Margaret study in Rave as requested by D.Laurence. mc 11/28/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Doxorubicin Concentration in","type":"Preferred Question Text","description":"Doxorubicin Concentration in Lung Tissue","url":null,"context":"NCIP"}],"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42648C33-74E4-3242-E053-F662850A843E","latestVersionIndicator":"Yes","beginDate":"2016-11-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-11-28","modifiedBy":"COOPERM","dateModified":"2016-12-07","changeDescription":"Created for Princess Margaret study in Rave as requested by D.Laurence. mc 11/28/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}